Table 1.

Compound-induced growth inhibition in UOK cells with/without FLCN

CompoundsGI50 (nmol/L)GI50 (nmol/L)GI50 Ratio
in UOK-FLCNin UOK-FLCN+of UOK-FLCN+/UOK-FLCN
Morpholino-ADR0.45 ± 0.03 (3)0.44 ± 0.10 (3)0.97
Cyanomorpholino-ADR3.79 ± 0.39 (3)0.62 ± 0.16 (3)0.16
Echinomycin5.72 ± 0.22 (3)4.03 ± 0.89 (3)0.71
Didemnin B7.94 ± 1.66 (4)6.53 ± 1.78 (4)0.82
Vincristine sulfate30.1 ± 10.3 (5)56.4 ± 17.5 (5)1.88
Chromomycin A337.4 ± 6.9 (3)33.0 ± 5.7 (3)0.88
Mithramycin64.2 ± 7.9 (3)634 ± 148 (4)9.88
Bruceantin68.4 ± 14.9 (3)43.6 ± 5.1 (3)0.64
Paclitaxel (taxol)75.5 ± 9.2 (5)514 ± 86 (3)6.81
Phyllanthoside199 ± 79 (5)427 ± 97 (4)2.15
Doxorubicin (adriamycin)423 ± 54 (3)581 ± 109 (4)1.37
Menogaril588 ± 57 (4)757 ± 117 (4)1.29
VM-26 (teniposide)773 ± 162 (3)849 ± 358 (3)1.10
Bisantrene hydrochloride1753 ± 288 (6)1345 ± 602 (5)0.77
N,N-dibenzyldaunomycin5739 ± 918 (4)1273 ± 549 (4)0.22

NOTE: Data are mean ± SE with the number of the experiments given in parenthesis. GI50 values were calculated by fitting a sigmoidal concentration/inhibition curve to the results using nonlinear least square regression (GraphPad PRISM) to data generated by the SRB assay.